# EU PV for Retapamulin-Prescribing

> **NCT01153828** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Impetigo

## Interventions

- **DRUG:** Retapamulin
- **DRUG:** Co-prescription of retapamulin and topical mupirocin
- **DRUG:** Co-prescription of retapamulin and topical fusidic acid

## Key facts

- **NCT ID:** NCT01153828
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153828, "EU PV for Retapamulin-Prescribing". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01153828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*